Ferring Opens New Research Center

Xconomy San Diego — 

Switzerland’s Ferring Pharmaceuticals, which established the Ferring Research Institute in San Diego in 1996, celebrated the opening of its new research facility here last night. Ferring describes itself as a leading biopharmaceuticals center for peptide research, and last night’s event also provided an opportunity for the Swiss pharma to promote degarelix, the first peptide “new chemical entity” discovered by the Ferring Research Institute in San Diego. The drug, which was recently approved by the FDA as a treatment for prostate cancer, is expected to enter the U.S. market by the end of March.